SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-009483
Filing Date
2022-03-10
Accepted
2022-03-10 08:10:33
Documents
15
Period of Report
2022-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20220310.htm   iXBRL 8-K 35554
2 EX-99.1 achv-ex991_6.htm EX-99.1 310895
3 GRAPHIC gvu0kizfhbom000001.jpg GRAPHIC 18627
4 GRAPHIC gvu0kizfhbom000004.jpg GRAPHIC 24282
  Complete submission text file 0001564590-22-009483.txt   552121

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA achv-20220310.xsd EX-101.SCH 5721
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20220310_lab.xml EX-101.LAB 20149
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20220310_pre.xml EX-101.PRE 12047
9 EXTRACTED XBRL INSTANCE DOCUMENT achv-8k_20220310_htm.xml XML 3676
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 22727491
SIC: 2835 In Vitro & In Vivo Diagnostic Substances